{
  "disease_features": {
    "iMCD-TAFRO": {
      "TNF_pathway_evidence": 2.0,
      "IL6_pathway_evidence": 2.0,
      "CD4_T_cell_involvement": 2.0,
      "rare_disease": true,
      "mortality_risk": "high"
    }
  },
  "drug_features": {
    "adalimumab": {
      "TNF_inhibitor": true,
      "experimental_evidence_score": 2.0,
      "mechanism_match": "direct",
      "clinical_evidence": true
    },
    "tocilizumab": {
      "IL6_inhibitor": true,
      "current_standard": true,
      "limited_efficacy": true
    },
    "siltuximab": {
      "IL6_inhibitor": true,
      "FDA_approved": true,
      "limited_efficacy": true
    }
  },
  "gene_features": {
    "TNF": {
      "fold_change_naive_cd4": 4.94,
      "functional_validation": true,
      "pathway_centrality": "high",
      "therapeutic_target": true
    },
    "IL6": {
      "pathway_enrichment": "high",
      "established_target": true
    }
  },
  "cell_type_features": {
    "naive_CD4_T_cell": {
      "TNF_production_fold": 2.53,
      "disease_driver": true,
      "therapeutic_relevance": "high"
    }
  }
}